Skip to main content
Thai Ho, MD, Oncology, Phoenix, AZ, Mayo Clinic Hospital

ThaiHuuHoMDPhD

Oncology Phoenix, AZ

Genitourinary Oncology, Hematologic Oncology

Associate Professor, Internal Medicine, Mayo Medical School

Dr. Ho is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Ho's full profile

Already have an account?

Clinical Expertise

  • Alternative Splicing, RNA Splicing, Cell Line, Histone Code, Kidney Neoplasms, Renal cell carcinoma, Therapeutics, Urologic oncology, Hematologic oncology, General medical oncology, Urethral cancer

Education & Training

  • University of Texas Health Science Center at Houston/M D Anderson Cancer Center
    University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2006 - 2009
  • Baylor College of Medicine
    Baylor College of MedicineClass of 2006

Certifications & Licensure

  • SC State Medical License
    SC State Medical License 2023 - 2025
  • AZ State Medical License
    AZ State Medical License 2012 - 2025
  • TX State Medical License
    TX State Medical License 2009 - 2024
  • CA State Medical License
    CA State Medical License 2012 - 2021
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Young Investigator Award ASCO
  • Paul Calabresi Career Development Award (K12) Mayo Clinic Cancer Center

Clinical Trials

Publications & Presentations

PubMed

Grant Support

  • Synthetic Lethal Targeting of SETD2 in Renal Cell CarcinomaNIH-NCI2023–2028
  • Deciphering the Interplay Between H3K36 and DNA Methylation in Renal CancerNIH-NCI2018–2023
  • Reprogramming Chromatin Modifiers in Kidney CancerDepartment of Defense2017–2020
  • Functional characterization of pazopanib or sunitinib on T cell functionNovartis2017–2018
  • Study of a Newly Discovered Immune Cell in the Blood and Evaluation of Its Potential Medical ApplicationsDepartment of Defense2015–2016
  • Identifying Epigenetically Regulated Pathways to Target Kidney Cancer MetastasesNIH2013–2016
  • Papillary Renal Cell and Urothelial Carcinomas Sample SubmissionNational Institutes of Health2013–2014
  • The Role of SETD2, a Histone Methyltransferase, in the Development of Renal Cell CarcinomaConquer Cancer Foundation2011–2012

Professional Memberships

Hospital Affiliations